The use of preimplantation genetic testing for aneuploidy: a committee opinion

Practice Committee of the American Society for Reproductive Medicine and the Society for Assisted Reproductive Technology. Electronic address: jhayes@asrm.org

doi:10.1016/j.fertnstert.2024.04.013

The use of preimplantation genetic testing for aneuploidy: a committee opinion

Fertil Steril. 2024 May 18:S0015-0282(24)00241-3. doi: 10.1016/j.fertnstert.2024.04.013. Online ahead of print.

Author

Practice Committee of the American Society for Reproductive Medicine and the Society for Assisted Reproductive Technology. Electronic address: jhayes@asrm.org¹

Affiliation

¹ American Society for Reproductive Medicine, Washington, D.C.

PMID: 38762806
DOI: 10.1016/j.fertnstert.2024.04.013

Abstract

The use of preimplantation genetic testing for aneuploidy (PGT-A) in the United States has been increasing steadily. Moreover, the underlying technology used for 24-chromosome analysis continues to evolve rapidly. The value of PGT-A as a routine screening test for all patients undergoing in vitro fertilization has not been demonstrated. Although some earlier single-center studies reported higher live-birth rates after PGT-A in favorable-prognosis patients, recent multicenter, randomized control trials in women with available blastocysts concluded that the overall pregnancy outcomes via frozen embryo transfer were similar between PGT-A and conventional in vitro fertilization. The value of PGT-A to lower the risk of clinical miscarriage is also unclear, although these studies have important limitations. This document replaces the document of the same name, last published in 2018.

Keywords: PGT; PGT-A; Reproductive medicine; aneuploidy; reproductive science.